Emily Kopp, Web Producer at Kaiser Health News, most recently worked as a freelance reporter. She has previously worked at Politico and AIS Health. Before that, she interned with the Center for Responsive Politics.
Emily Kopp
From this contributor
Nonprofit with ties to pharma launches campaign against drug imports
Both the Pharmaceutical Research and Manufacturers of America and the nonprofit group have gone to great lengths to show that drugmakers are not driving what they describe as a “grass-roots” effort to fight imports.
Nonprofit with ties to pharma launches campaign against drug imports
By
Emily Kopp, Rachel Bluth, Kaiser Health News
20 April 2017 | 8 min read
Senators want answers about reported probe of U.S. health secretary
Nine U.S. senators are pushing the U.S. Attorney General to reveal what he knows about a reported investigation into Tom Price’s stock trades that a top federal prosecutor might have begun before being fired by the Trump administration.
Senators want answers about reported probe of U.S. health secretary
By
Emily Kopp, Rachel Bluth, Kaiser Health News
31 March 2017 | 4 min read
Most patient advocacy groups accept funding from pharma
At least 83 percent of the United States' largest patient advocacy groups take contributions from the drug industry, and not all of them are transparent about it.
Most patient advocacy groups accept funding from pharma
By
Emily Kopp, Kaiser Health News
2 March 2017 | 5 min read
Explore more from The Transmitter
Is it time for neuroscience to shift its focus from a computational mind to a navigating mind?
Andrea Hiott explains her navigational approach to the mind, and why now is the time to embrace seemingly paradoxical findings in neuroscience.
Is it time for neuroscience to shift its focus from a computational mind to a navigating mind?
Andrea Hiott explains her navigational approach to the mind, and why now is the time to embrace seemingly paradoxical findings in neuroscience.
By
Paul Middlebrooks
21 October 2026 | 1 min read
Human brain organoids come of age—but still have room to grow
The U.S. government has touted organoids as an alternative to animals for studying the brain. The model has improved since its debut in 2013, but scientists are still working to overcome key limitations: immaturity, consistency and the lack of vascularization.
Human brain organoids come of age—but still have room to grow
The U.S. government has touted organoids as an alternative to animals for studying the brain. The model has improved since its debut in 2013, but scientists are still working to overcome key limitations: immaturity, consistency and the lack of vascularization.
By
Claudia López Lloreda
21 October 2026 | 9 min read
Finding neuroheterogeneity’s sweet spot
Once thought to be detrimental to memory processing, neuronal diversity—at the right ‘Goldilocks’ dose—is a new boon to theoretical neuroscience.
Finding neuroheterogeneity’s sweet spot
Once thought to be detrimental to memory processing, neuronal diversity—at the right ‘Goldilocks’ dose—is a new boon to theoretical neuroscience.
By
Natalia Mesa
20 October 2026 | 7 min read